Current status of human melanoma vaccines. Can they control malignant melanoma?

BioDrugs

Volumn 7, Issue 1, 1997, Pages 66-84

  Hoon, Dave S B ^a   Irie, Reiko F ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT; MELANOMA ANTIGEN; MELANOMA VACCINE;

CANCER REGRESSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MANUFACTURE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0030858382     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199707010-00008     Document Type: Review

References (121)

1. Koh HK. Cutaneous melanoma. N Engl J Med 1991; 325: 171-82
2. Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995; 75: 726-34
3. Barth AM, Irie RF, Morton DL. Update on immunotherapy for advanced melanoma. Contemp Oncol 1994; 4 (10): 52-60
4. Morton DL, Essner R, Kirkwood JM, et al. Malignant melanoma. In: Holland JF, et al., editors. Cancer medicine. 4th ed. Baltimore: Williams & Wilkins, 1996. In press
5. Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-82
6. Hom SS, Topalian SL, Simonis T, et al. Common expression of melanoma tumour-associated antigens recognized by human tumour infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J Immunother 1991; 10: 153-64
7. Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993; 177: 989-98
8. Livingston PO, Natoli Jr EJ, Calves MJ, et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989; 49: 7045-50
9. Jones PC, Sze LL, Liu PY, et al. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 1981; 66: 249-54
10. Unanue ER. Macrophages, antigen-presenting cells and the phenomena of antigen handling and presentation. In: Paul WE, editor. Fundamental immunology. 3rd ed. New York: Raven Press, 1993: 111-44
11. Slingluff Jr CL, Seigler HF. Immunotherapy for malignant melanoma with a tumour cell vaccine. Ann Plast Surg 1992; 28: 104-7
12. Livingston PO, Wong GYC, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036-44
13. Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J Surg 1992; 16: 251-60
14. Bystryn JC, Henn M, Li J, et al. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res 1992; 52: 5948-53
15. Berd D, Maguire Jr HC, McCue P, et al. Treatment of metastatic melanoma with an autologous tumour-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990; 8: 1858-67
16. Wallack MK, Sivandandham M, Balch CM, et al. A phase III randomized, double-blind multi-institutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995; 75: 34-42
17. Mitchell MS, Harel W, Kan-Mitchell J, et al. Active specific immunotherapy of melanoma with allogeneic cell lysates. Ann N Y Acad Sci 1993; 690: 153-66
18. Bornstein RS, Mastrengelo MJ, Sulit H. Immunotherapy of melanoma with intralesional BCG. NCI Monogr 1973; 39: 213-20
19. Ada GL. The immunological principles of vaccination. Lancet 1990; 335: 523-6
20. Arnon R, Van Regenmortel MHV. Structural basis of antigenic specificity and design of new vaccines. FASEB J 1992; 6: 3265-74
21. Elliot GT, McLeod RA, Perez, J, et al. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (Theracine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol 1993; 9: 264-72
22. Greene MH, Clark WH, Tucker MA, et al. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985; 102: 458-65
23. Hoon DS, Foshag LJ, Nizze AS, et al. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 1990; 50: 5358-64
24. Hoon DSB, Korn EL, Cochran AJ. Variations in functional immunocompetence of individual tumour-draining lymph nodes in humans. Cancer Res 1987; 47: 1740-44
25. Hoon DSB, Bowker RJ, Cochran AJ. Suppressor activity in melanoma-draining lymph nodes. Cancer Res 1987; 47: 1529-33
26. Shibata M., Hoon D, Okun E, et al. Modulation of histamine type II receptors on CD8+ T cells by interleukin 2 and cimetidine. Int Arch Allergy Immunol 1992; 97: 8-16
27. Hoon DSB, Irie RF, Cochran AJ. Ganglioside from human melanoma immunomodulate response of T cells to interleukin 2. Cell Immunol 1988; 111: 410-9
28. Cochran AJ, Wen D-R, Stene M, et al. Immunobiology of human cutaneous melanoma. In: Advances in Pigment Cell Research. New York: Alan R. Liss, 1988: 597-618
29. Old, LJ. Cancer immunology: The search for specificity. Cancer Res 1981; 41: 361-75
30. Kawakami Y, Eliyau S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumour. Proc Natl Acad Sci USA 1994; 91: 3515-9
31. Adema GJ, de Boer AJ, Vogel AM, et al. Molecular characterization of melanocyte lineage-specific antigen gp100. J Biol Chem 1994; 269: 20126-33
32. Kwon BS. Pigmentation genes: the tyrosinase gene family and pmel17 gene family. J Invest Dermatol 1993; 100: 1345-405
33. Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med 1990; 171: 1375-80
34. Orlow SJ, Boissy RE, Moran DJ, et al. Subcellular distribution of tyrosinase and tyrosinase-related protein-1: implications for melanosomal biogenesis. J Invest Dermatol 1993; 100: 55-64
35. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocyte on HLA-A2 melanomas. J Exp Med 1993: 178; 489-95
36. Traversari C, Van der Bruggen P, Leuscher JF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumour antigen MZ2-E. J Exp Med 1992; 176: 1453-7
37. Van der Bruggen, Traversari PC, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991: 254; 1643-7
38. Gaugler B, Van den Eynde B, Van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994: 179; 921-30
39. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognition on human melanoma of cytolytic T lymphocytes. Immunity 1995; 2: 167-75
40. Albino AP, Nanus DM, Mentle IR, et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 1989; 4: 1363-74
41. Holstein M, Sidransky D, Vogelstein B, et al. P53 mutations in human cancer. Science 1991; 253: 49-53
42. Stretch JR, Gatter KC, Ralfkiaer E, et al. Expression of mutant 53 in melanoma. Cancer Res 1991: 51; 5976-9
43. Tai T, Paulson JC, Cahan LD, et al. Ganglioside GM2 as a human tumour antigen (OFA-I-I). Proc Natl Acad Sci USA 1983; 80: 5392-6
44. Tsuchida T, Saxton RE, Morton DL, et al. Gangliosides of human melanoma. J Natl Cancer Inst 1987; 78: 45-54
45. Cahan LD, Irie RF, Singh R, et al. Identification of a human neuroectodermal tumour antigen (OFA-1-2) as ganglioside GD2. Proc Natl Acad Sci USA 1982: 79; 7629-33
46. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045
47. Mitchison NA. Specialization, tolerance, memory, competition, latency, and strife among T cells. Annu Rev Immunol 1992; 10: 1-12
48. Ada L. Vaccines. In: Paul WE, editor. Fundamental immunology. New York: Raven Press, 1993: 1309-52
49. Berd D, Maguire Jr HC, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986; 46: 2572-7
50. Berd D, Maguire Jr HC, Mastrangelo MJ, et al. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol Immunother 1994; 39: 141-7
51. Murphy GF, Radu A, Kaminer M, et al. Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy. J Invest Dermatol 1993; 100: 335S-41S
52. Mitchison NA. Immunologic approach to cancer. Transplant Proc 1970; 11: 92-103
53. Fujiwara H, Aoki H, Yoshioka T, et al. Establishment of a tumour-specific immunotherapy model utilizing TNP-reactive helper cell activity and its application to the autochthonous tumour system. J Immunol 1984; 133: 509-14
54. Roth JA, Morton DL, Holmes HD. Rejection of dinitrochlorobenzene-conjugated syngeneic tumour cells by dinitrochlorobenzene-sensitized guinea pigs. J Surg Res 1978; 25: 1-6
55. Morton DL, Hoon DS, Nizze JA, et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann NY Acad Sci 1993: 690; 120-34
56. Ravindranath MH, Morton DL, Irie RF. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibody in melanoma patients after active specific immunotherapy. Cancer Res 1989; 49: 3891-7
57. Euhus DM, Gupta RK, Morton DL. Induction of antibodies to a tumour-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 1989; 29: 247-54
58. Gupta RK, Morton DL. Immunochemical characterization of fetal antigen isolated from spent media of a human melanoma cell line. J Natl Cancer Inst 1983; 70: 993-1003
59. Gupta RK, Morton DL. Studies of a melanoma tumour associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody. I. Purification and development of a radioimmunoassay. J Natl Cancer Inst 1984; 72: 67-74
60. Morioka N, Kikumoto Y, Hoon DSB, et al. Adecapeptide (Gln-Asp-Leu-Thr-Met-Lys-Tyr-Gln-Ile-Phe) from human melanoma is recognized by CTL in melanoma patients. J Immunol 1994; 153: 5650-8
61. Barth A, Hoon DS, Foshag LJ, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994; 54: 3342-5
62. Nakarai H, Chandler PJ, Kano DL, et al. Hanganutziu-Deicher antigen as a possible target for immunotherapy of melanoma. Int Arch Allergy Appl Immunol 1990; 91: 323-8
63. Hoon DSB, Yuzuki D, Hayashida M, et al. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 1995; 154: 730-7
64. Morioka N, Kikumoto Y, Hoon DSB, et al. Cytotoxic T cell recognition of a human melanoma derived peptide with a carboxyl-terminal alanine-proline sequence. Mol Immunol 1995; 32: 573-81
65. Hoon DS, Morisaki T, Uchiyama A, et al. Augmentation of T-cell response with a melanoma cell vaccine expressing specific HLA-A antigens. Ann NY Acad Sci 1993; 690: 343-5
66. Hayashi Y, Hoon DS, Foshag LJ, et al. A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine. Cancer 1993; 72: 750-9
67. Hayashi Y, Hoon DSB, Park MS, et al. Induction of CD4+ cytolytic T cells by sensitization with allogeneic melanoma bearing shared or cross-reactive HLA-A. Cell Immunol 1992; 139: 411-25
68. Hayashi Y, Hoon DSB, Park MS, et al. Cytotoxic T cell lines recognize autologous and allogeneic melanoma with shared a cross-reactive HLA-A. Cancer Immunol Immunother 1992; 34: 419-23
69. Zatloukal K, Schneeburger A, Berger M, et al. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2 based vaccine. J Immunol 1995; 154: 3406-19
70. Dranoff G, Jaffee E, Lazenby A, et al. Vaccinated with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumour immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43
71. Porgador A, Gansbacher B, Bannerji R, et al. Anti-metastatic vaccination of tumour-bearing mice with IL-2 gene inserted tumour cells. Int J Cancer 1993; 53: 471-7
72. Fenton RT, Sznol M. A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumour-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. Human Gene Ther 1995; 6: 87-106
73. Cascinelli N, Foa R, Parmiani G. Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells: a phase I-II study. Human Gene Ther 1994; 5: 1059-64
74. Osanto S, Brouwenstjin N, Vaessen N, et al. Gene therapy of metastatic melanoma patients with IL-2 transfected melanoma cells [abstract]. Proc Am Soc Clin Oncol 1994; 13: 293
75. Rankin KM, Spits H, Orsini D, et al. A phase I study of vaccination with autologous. GM-CSF-transduced and irradiated tumour cells in patients with advanced melanoma [abstract]. Proc Am Soc Clin Oncol 1995; 14: 226
76. Golumbek PT, Azhari R, Jaffee EM, et al. Continual release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 1993; 53: 5841-4
77. Mitchell MS, Liggett PH, Green RL, et al. Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine. J Clin Oncol 1994: 12; 396-401
78. Hersey P, Werkman H, Edwards AE. Western blot analysis of serological responses following immunization with vaccinia viral lysates of melanoma cells. Int J Cancer 1990; 46: 612-7
79. Wallack M, Sivandham M, Balch C, et al. A phase III randomized multi-institutional double-blind adjuvant study of vaccinia melanoma oncolysate (VMO) vs. vaccinia (V) alone in stage II melanoma [abstract]. Proc Am Soc Clin Oncol 1994; 13: 64
80. Berthier-Vergnes O, Portoukalian J, Leftheriotis E, et al. Induction of IgG antibodies directed to a Mr 31 000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates. Cancer Res 1994; 54: 2433-9
81. Miller K, Abeles G, Oratz R, et al. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 1995; 75: 495-502
82. Bystryn JC, Oratz R, Roses D, et al. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 1992; 69: 1157-64
83. Oratz R, Cockerell C, Speyer JL, et al. Induction of tumour-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine. J Biol Response Mod 1989; 8: 355-8
84. Schultz N, Oratz R, Chen D, et al. Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 1995; 6: 503-8
85. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanoma by autologous cytolytic T lymphocytes. Eur J Immunol 1994; 24: 759-64
86. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumour-infiltrating T lymphocytes associated with in vivo tumour regression. J Immunol 1995; 154: 3961-8
87. Darrow T, Singluff CL, Seigler HF. The role of HLA class I antigen in the recognition of melanoma cells by tumour-specific cytotoxic T lymphocytes: evidence for shared tumour antigen. J Immunol 1989; 142: 3329-35
88. Visseren MJW, van Elsas A, van der Voort EIH, et al. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 1995; 154: 3991-8
89. Storkus WJ, Zeh III H, Maeuer MJ, et al. Identification of human melanoma peptides recognized by class I restricted tumour infiltrating T lymphocytes. J Immunol 1993; 151: 3719-27
90. Castelli C, Storkus WJ, Maeurer MJ, et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995; 181: 363-8
91. Cellis E, Tsai V, Crimi C, et al. Induction of anti-tumour cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994; 91: 2105-9
92. Cox AL, Skipper J, Che Y, et al. Identification of a peptide recognized by five melanoma specific human cytotoxic T cell lines. Science 1994; 264: 716-9
93. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153: 5586-92
94. Helling F, Zhang S, Shang A, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995; 55: 2783-8
95. Livingston PO, Adluri S, Helling F, et al. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 1994; 12: 1275-80
96. Nepom GT, Hellstrom KE. Anti-idiotypic antibodies and induction of specific tumour immunity. Cancer Metastasis Rev 1987; 6: 489-502
97. Chen ZJ, Yang H, Kageshita T, et al. Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody TK7-371. Cancer Res 1991; 51: 2599-604
98. Kusama M, Kaeshita T, Tsujisaki M., et al. Syngeneic anti-idiotypic antisera to murine antihuman high molecular weight melanoma-associated antigen monoclonal antibodies. Cancer Res 1987; 47: 4312-7
99. Mittelman A, Chen GZJ, Wong GY, et al. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1995; 1: 705-13
100. Ertl HCJ, Bona CA. Criteria to define anti-idiotypic antibodies carrying the internal image of an antigen. Vaccine 1988; 6: 80-4
101. Saleh MN, Stapleton JD, Khazaeli MB, et al. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J Immunology 1993; 151: 3390-8
102. Yamamoto S, Yamamoto T, Saxton RE, et al. Anti-idiotype monoclonal antibody carrying the internal image of ganglioside GM3. J Natl Cancer Inst 1990; 82: 1757-60
103. Chapman PB, Houghton AN. Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J Clin Invest 1991; 88: 186-92
104. Mittelman A, Chen ZJ, Yang H, et al. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992; 89: 466-70
105. Chattopadhyay P, Starkey J, Morrow WJ, et al. Murine monoclonal anti-idiotype antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys. Proc Natl Acad Sci USA 1992; 89: 2684-8
106. Mossman TR, Schumacher JH, Street NF, et al. Diversity of cytokine synthesis and function of mouse CD4+ T cells. Immunol Rev 1991; 123: 209-29
107. Estin CD, Stevenson US, Plowman GD, et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci USA 1988; 85: 1052-6
108. Coonery EL, Collier AC, Greenberg PD, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991; 337: 565-72
109. Berkner KL. Expression of heterologous sequences in adenoviral vectors. Curr Top Microbiol Immunol 1992; 159: 39-66
110. Alpuche-Aranda C, Swanson J, Loomis W, et al. Salmonella typhimurium activates virulence gene transcription within acidified macrophage phagosomes. Proc Natl Acad Sci USA 1992; 89: 10079-83
111. Flynn JL, Weiss WR, Norris KA, et al. Generation of a cytotoxic T-lymphocyte response using a Salmonella antigen-delivery system. Mol Microbiol 1990; 4: 111-8
112. Michel M-L, Davis HL, Schleef M, et al. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 1995; 92: 5307-11
113. Ulmer JB, Donnely JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-9
114. Hoon DSB, Kaneda Y. Induction of anti-MAGE-1 and -3 immune response by DNA plus liposome vaccination. Submitted
115. Phillips NC, Loufti A, A-Kareem M, et al. Clinical evaluation of liposomal tumour antigen vaccines in patients with stage-III melanoma. Cancer Detect Prev 1990; 14: 491-6
116. Cooper PD. The selective induction of different immune responses by vaccine adjuvants. In: Ada GL, editor. Strategies in vaccine design. Austin (TX): RG Landes Company, 1994: 125-58
117. Yamamoto S, Yamamoto T, Kataoka T, et al. Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity. J Immunol 1992; 148: 4072-6
118. Yamamoto T, Yamamoto S, Katoaoka T, et al. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their hase length. Antisense Res Dev 1994: 119-22
119. Kirkwood JM. Systemic therapy of melanoma. Curr Opin Oncol 1994; 6: 204-11
120. Chachoua A, Oratz R, Liebes L, et al. Phase 1b trial of granulocyte-macrophage colony-stimulating factor induced with murine monoclonal antibody R24 in patients with metastatic melanoma. J Immunother Emphasis Tumour Immunol 1994; 16: 132-41
121. Hoon DSB, Wang Y, Dale PS, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995; 13: 2109-16